Literature DB >> 29894272

Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies.

Josh Sopp1, Mark S Cragg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29894272     DOI： 10.1200/JCO.2018.78.7390

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Authors:  Ciara L Freeman; Laurie Sehn
Journal:  Curr Oncol Rep       Date:  2018-11-27       Impact factor: 5.075

2.  The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.

Authors:  Mitchell Evers; Thies Rösner; Anna Dünkel; J H Marco Jansen; Niklas Baumann; Toine Ten Broeke; Maaike Nederend; Klara Eichholz; Katja Klausz; Karli Reiding; Denis M Schewe; Christian Kellner; Matthias Peipp; Jeanette H W Leusen; Thomas Valerius
Journal:  Blood Adv       Date:  2021-10-12

Review 3.  Targets and Antibody Formats for Immunotherapy of Neuroblastoma.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2020-03-13       Impact factor: 44.544

4.  A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

Authors:  Edward Fox; Amy E Lovett-Racke; Matthew Gormley; Yue Liu; Maria Petracca; Sirio Cocozza; Richard Shubin; Sibyl Wray; Michael S Weiss; Jenna A Bosco; Sean A Power; Koby Mok; Matilde Inglese
Journal:  Mult Scler       Date:  2020-04-30       Impact factor: 6.312

5.  Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy.

Authors:  Russell Foxall; Priyanka Narang; Bridget Glaysher; Elin Hub; Emma Teal; Mark C Coles; Margaret Ashton-Key; Stephen A Beers; Mark S Cragg
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.